Phase III Trial Confirms ORR in Previously Treated Patients who Received Opdivo October 20, 2016Vol.39 No.09
Yervoy Improved OS in Fully Resected Stage III Patients from Phase III Study October 20, 2016Vol.39 No.09
Phase III Tecentriq Study Shows Better Survival vs. Chemo Regardless of PD-L1 Status October 20, 2016Vol.39 No.09
Drugs & Targets Novartis, MEI Pharma. Receive Breakthrough Therapy Designations September 22, 2016Vol.39 No.08
Study Confirms Association Between RFA Burn Time, OS In Patients Receiving ThermoDox September 22, 2016Vol.39 No.08
